Machine learning-based QSAR and structure-based virtual screening guided discovery of novel mIDH1 inhibitors from natural products.

Journal: Journal of computer-aided molecular design
Published Date:

Abstract

Mutations in isocitrate dehydrogenase 1 (IDH1) have been widely observed in various tumors, such as gliomas and acute myeloid leukemia, and therefore has become one of the current research focal points. Therefore, it is crucial to find inhibitors that could target mIDH1, which may provide more effective treatment options for patients with related tumors. In present study, combines machine learning-based QSAR models and structure-based virtual screening to screen a series of potential IDH1 inhibitors from the Coconut databases. The QSAR model predictions indicate that the hit compounds have high binding affinity to the target protein, and its pIC value was found to be considerably larger than that of AGI-5198. The RMSD and Rg analysis demonstrated that all of the ligand-protein complexes exhibited a stable state throughout the simulation period. Furthermore, the binding free energy decomposition and per-residue contribution of the IDH1-inhibitor complex revealed key fragments of the inhibitor interacting with residues ALA-111, PRO-118, ARG-119, LE-128, ILE-130, ITRP-267, VAL-281, and TYR-285 in the binding site of IDH1. This investigation indicates that CNP0047068, CNP0029964, and CNP0025598 have the potential to be targeted inhibitors of IDH1 mutants through further optimization, providing new insights for discovering novel lead scaffolds in this domain.

Authors

  • Hailong Bai
    R&D Department, Deepcare Inc., Beijing, China.
  • Yalong Cheng
    Lintong Sanatorium Center of the People's Liberation Army Joint Logistic Support Force, Xi'an, Shaanxi Province, China.
  • Shunjiang Jia
    College of Pharmacy, Shaanxi University of Chinese Medicine, Shiji Ave, Xi'an-Xianyang New Economic Zone, Shaanxi Province, China.
  • Xiaorui Wang
    Structural Biophysics Group, School of Optometry and Vision Sciences, Cardiff University, Cardiff, Wales, UK.
  • Ruyi Jin
    College of Pharmacy, Shaanxi University of Chinese Medicine, Shiji Ave, Xi'an-Xianyang New Economic Zone, Shaanxi Province, China.
  • Hui Guo
    Health Sciences and Innovation, Surrey Memorial Hospital, Fraser Health Authority, Surrey, BC, Canada.
  • Yuping Tang
    Department of Obstetrics, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai 201204, China.
  • Yuwei Wang
    College of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang, 712000, PR China.